Meet the era of "innovative medicine" 1 pharmaceutical network to build an all channel commercial platform

On December 11, 1 pharmaceutical network, a leading enterprise of Internet medicine and health in China, held the "science and technology empowering and win-win cooperation - 2019 Second China Internet medicine and health summit and 1 pharmaceutical Network Partner Conference" in Shanghai At the conference, 1 pharmaceutical network comprehensively upgraded the t2b2c strategy, put forward for the first time to build an all-channel commercial platform, and launched the original research drug welfare plan for the C-end, comprehensively Help pharmaceutical companies cope with the post-4 + 7 era The conference attracted nearly 600 guests from well-known pharmaceutical enterprises, medical industry, pharmacies, investment institutions and government leaders at home and abroad This is an industry grand meeting with the largest number of middle and high-level Chinese and foreign pharmaceutical enterprises after the expansion of volume procurement The meeting focused on the impact of 4 + 7 volume procurement expansion and Internet enabled pharmaceutical enterprises In 2019, with the volume of procurement from the pilot to expand the country, the pharmaceutical industry ushered in a landmark change Standing at the new starting point of the new medical reform in the past 10 years, how to deal with the post "4 + 7" era? As the host, Dr Yu Gang, the co-founder and executive chairman of 1 pharmaceutical network, and Liu Junling, the co-founder and chairman and CEO of 1 pharmaceutical network, comprehensively and deeply elaborated the all channel commercialization platform strategy of 1 pharmaceutical network for pharmaceutical enterprises at the conference After one year's practice and exploration, this year 1 pharmaceutical network has upgraded the t2b2c strategy in an all-round way In addition to further enriching the empowering system of pharmaceutical enterprises, pharmacies, patients and insurance enterprises, it has also added an organizational empowering system, and formally proposed a full life cycle management scheme for patients Through CRM system, we can provide all-round patient management services, enhance service stickiness, improve medication compliance, and improve the continuation rate With the expansion of volume procurement, the future market will be the world of innovative drugs The biggest demand for innovative drugs is how to achieve commercialization In this regard, for the first time, 1 pharmaceutical network innovatively put forward the strategy of Omni channel commercialization platform 1 Pharmaceutical network should make use of its online and offline integrated medical and health platform to help pharmaceutical enterprises to cover drugstores, clinics, private hospitals, community hospitals, 3-6 hospitals and patients beyond the 1-2 urban hospitals and large chain drugstores, so as to provide complementary value-added services for pharmaceutical enterprises In addition to building platform support, 1 pharmaceutical network also proposed for the first time to build a decentralized academic promotion platform for medical representatives - Shizhen, which aims to promote pharmaceutical market education through professional content services At present, the website has successfully recruited 1000 medical representatives In addition, 1 drug network also launched the original research drug welfare plan for C-terminal, aiming to enable patients, enhance patients' drug compliance, and help pharmaceutical enterprises improve the accessibility of the original research drug through systematic operation of the whole process, such as doctor consultation, medication guidance, online follow-up, pharmacist service, etc Yu Gang stressed that 1 Through model innovation and advanced technology application, pharmaceutical network should be the first choice of all channel commercialization platform for pharmaceutical enterprises and the first choice of medical and health service platform for patients With the deep expansion of volume procurement across the country, the pharmaceutical industry has seen a scene of thousands of troops competing for a single timber bridge Although the country has tightened the door of the hospital market, it has also opened a door for pharmaceutical enterprises to a broad market outside the hospital - the Internet channel At the meeting, Dr Chen Lianyong, founder partner and CEO of Tonghe Yucheng, and Wu Kun, general manager of Pfizer biopharmaceutical group in China, delivered keynote speeches from the perspective of pharmaceutical professional investment institutions and multinational pharmaceutical enterprises respectively In the first round of "4 + 7 in-depth expansion: new challenges and opportunities for pharmaceutical enterprises, terminals and patients", Liu Junling and Feng Yanhui, general manager of Weicai China, Xia Chun, general manager of Sanofi China's business and emerging business, Guo Anfeng, vice president of BMS China's immune tumor business, Xin Huibo, head of generic pharmaceutical business of Novartis (China) Pharmaceutical Co., Ltd There was an in-depth dialogue Four pharmaceutical enterprise guests acknowledged the omni channel commercialization platform strategy proposed by 1 pharmaceutical network According to Feng Yanhui, the Internet can speed up the market access process of innovative drugs, and it will be better to promote the acceptance and experience of commercial markets through public platforms In another round table dialogue, "policy dividend release: how the Internet enables the upgrading of the pharmaceutical industry" became the focus Zhang Kai, CEO and general manager of Zhonghong insurance, Li Jinhui, general manager of tumor and rare disease business of Pfizer biopharmaceutical group in China, Zhang Meng, vice president of Tencent medical, and other important guests participated in the dialogue When Chen Yang, CFO of the host 1 pharmaceutical network, asked what improvements the Internet had brought to the pharmaceutical industry, Zhang Kai thought that the Internet could significantly improve the depth, breadth and speed of medical services In the future, no matter the insurance enterprises, pharmaceutical enterprises and medical enterprises, they can build a patient-centered service system together with 1 pharmaceutical network.